These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23897861)

  • 1. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.
    Ito K; Yotsuyanagi H; Yatsuhashi H; Karino Y; Takikawa Y; Saito T; Arase Y; Imazeki F; Kurosaki M; Umemura T; Ichida T; Toyoda H; Yoneda M; Mita E; Yamamoto K; Michitaka K; Maeshiro T; Tanuma J; Tanaka Y; Sugiyama M; Murata K; Masaki N; Mizokami M;
    Hepatology; 2014 Jan; 59(1):89-97. PubMed ID: 23897861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan.
    Suzuki Y; Kobayashi M; Ikeda K; Suzuki F; Arfase Y; Akuta N; Hosaka T; Saitoh S; Kobayashi M; Someya T; Matsuda M; Sato J; Watabiki S; Miyakawa Y; Kumada H
    J Med Virol; 2005 May; 76(1):33-9. PubMed ID: 15779048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan.
    Ito K; Yotsuyanagi H; Sugiyama M; Yatsuhashi H; Karino Y; Takikawa Y; Saito T; Arase Y; Imazeki F; Kurosaki M; Umemura T; Ichida T; Toyoda H; Yoneda M; Tanaka Y; Mita E; Yamamoto K; Michitaka K; Maeshiro T; Tanuma J; Korenaga M; Murata K; Masaki N; Koike K; Mizokami M;
    J Gastroenterol Hepatol; 2016 Jan; 31(1):180-9. PubMed ID: 26110395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological Characteristics of Acute Hepatitis B in Eastern India: Critical Differences with Chronic Infection.
    Sarkar N; Pal A; Das D; Saha D; Biswas A; Bandopadhayay B; Chakraborti M; Ghosh M; Chakravarty R
    PLoS One; 2015; 10(11):e0141741. PubMed ID: 26571502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J; Wang Z; Zhou B; Wang Y; Hou J
    Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitis B.
    Yotsuyanagi H; Ito K; Yamada N; Takahashi H; Okuse C; Yasuda K; Suzuki M; Moriya K; Mizokami M; Miyakawa Y; Koike K
    Clin Infect Dis; 2013 Oct; 57(7):935-42. PubMed ID: 23704123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.
    Su CW; Wu CY; Hung HH; Wu CH; Sheen IJ; Wu JC
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1849-58. PubMed ID: 23730852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy.
    Hung CH; Chen CH; Lu SN; Wang JH; Hu TH; Huang CM; Tsai MC; Lee CM
    Antiviral Res; 2012 Jan; 93(1):55-63. PubMed ID: 22061616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
    Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
    Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epidemiological and clinical features of occult hepatitis B in HIV infection without antiretroviral treatment].
    Zhang RF; Liu L; Zheng YF; Shen YZ; Chen J; Gu SM; Wang JR; Lu HZ
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):189-91. PubMed ID: 23967739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
    Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.
    Jaroszewicz J; Calle Serrano B; Wursthorn K; Deterding K; Schlue J; Raupach R; Flisiak R; Bock CT; Manns MP; Wedemeyer H; Cornberg M
    J Hepatol; 2010 Apr; 52(4):514-22. PubMed ID: 20207438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment].
    Chen JJ; Wang ZH; Ma SW; Chen YP; Peng J; Guo YB; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):416-20. PubMed ID: 18578990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
    Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of hepatitis B virus (HBV) genotypes for the disease and treatment outcome among patients with chronic hepatitis B in Serbia.
    Milosevic I; Delic D; Lazarevic I; Pavlovic IP; Korac M; Bojovic K; Jevtovic D
    J Clin Virol; 2013 Sep; 58(1):54-8. PubMed ID: 23838671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan.
    Kobayashi M; Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Matsuda M; Sato J; Takagi K; Miyakawa Y; Kumada H
    J Med Virol; 2002 Dec; 68(4):522-8. PubMed ID: 12376960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
    Liang Y; Jiang J; Su M; Liu Z; Guo W; Huang X; Xie R; Ge S; Hu J; Jiang Z; Zhu M; Wong VW; Chan HL
    Aliment Pharmacol Ther; 2011 Aug; 34(3):344-52. PubMed ID: 21671967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    Nebbia G; Garcia-Diaz A; Ayliffe U; Smith C; Dervisevic S; Johnson M; Gilson R; Tedder R; Geretti AM
    J Med Virol; 2007 Oct; 79(10):1464-71. PubMed ID: 17705185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shifting hepatitis B virus genotypes of acute hepatitis B patients in northeast Japan.
    Inoue J; Kondo Y; Umetsu T; Yamamoto T; Miura M; Mano Y; Kobayashi T; Obara N; Niitsuma H; Kogure T; Nakagome Y; Kimura O; Iwata T; Morosawa T; Fujisaka Y; Shimosegawa T
    J Med Virol; 2016 Jan; 88(1):69-78. PubMed ID: 26113372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.